ATE263579T1 - Abgabe von polyethylene glycol-molekül- konjugaten aus abbaubarem hydrogel - Google Patents

Abgabe von polyethylene glycol-molekül- konjugaten aus abbaubarem hydrogel

Info

Publication number
ATE263579T1
ATE263579T1 AT98903543T AT98903543T ATE263579T1 AT E263579 T1 ATE263579 T1 AT E263579T1 AT 98903543 T AT98903543 T AT 98903543T AT 98903543 T AT98903543 T AT 98903543T AT E263579 T1 ATE263579 T1 AT E263579T1
Authority
AT
Austria
Prior art keywords
release
polyethylene glycol
glycol molecule
molecule conjugates
degradable hydrogel
Prior art date
Application number
AT98903543T
Other languages
English (en)
Inventor
J Milton Harris
Original Assignee
Debio Rech Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25509246&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE263579(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Debio Rech Pharma Sa filed Critical Debio Rech Pharma Sa
Application granted granted Critical
Publication of ATE263579T1 publication Critical patent/ATE263579T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G01N33/528—Atypical element structures, e.g. gloves, rods, tampons, toilet paper
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/508—Rigid containers without fluid transport within
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L99/00—Subject matter not provided for in other groups of this subclass
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/13—Burn treatment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815—Carrier is a synthetic polymer
    • Y10S530/816—Attached to the carrier via a bridging agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Clinical Laboratory Science (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT98903543T 1997-11-05 1998-01-23 Abgabe von polyethylene glycol-molekül- konjugaten aus abbaubarem hydrogel ATE263579T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/964,972 US6258351B1 (en) 1996-11-06 1997-11-05 Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
PCT/US1998/000918 WO1999022770A1 (en) 1997-11-05 1998-01-23 Delivery of poly(ethylene glycol)-conjugated molecules from degradable hydrogels

Publications (1)

Publication Number Publication Date
ATE263579T1 true ATE263579T1 (de) 2004-04-15

Family

ID=25509246

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98903543T ATE263579T1 (de) 1997-11-05 1998-01-23 Abgabe von polyethylene glycol-molekül- konjugaten aus abbaubarem hydrogel

Country Status (11)

Country Link
US (4) US6258351B1 (de)
EP (1) EP1028753B2 (de)
JP (1) JP3884615B2 (de)
AT (1) ATE263579T1 (de)
AU (1) AU752747B2 (de)
CA (1) CA2304976C (de)
DE (1) DE69823055T3 (de)
DK (1) DK1028753T4 (de)
ES (1) ES2219869T5 (de)
PT (1) PT1028753E (de)
WO (1) WO1999022770A1 (de)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100361933B1 (ko) * 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20020064546A1 (en) * 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
US8003705B2 (en) * 1996-09-23 2011-08-23 Incept Llc Biocompatible hydrogels made with small molecule precursors
US6566406B1 (en) 1998-12-04 2003-05-20 Incept, Llc Biocompatible crosslinked polymers
AU4648697A (en) * 1996-09-23 1998-04-14 Chandrashekar Pathak Methods and devices for preparing protein concentrates
US6258351B1 (en) * 1996-11-06 2001-07-10 Shearwater Corporation Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
US6362254B2 (en) * 1998-03-12 2002-03-26 Shearwater Corporation Poly(ethylene glycol) derivatives with proximal reactive groups
US7790192B2 (en) 1998-08-14 2010-09-07 Accessclosure, Inc. Apparatus and methods for sealing a vascular puncture
US6605294B2 (en) * 1998-08-14 2003-08-12 Incept Llc Methods of using in situ hydration of hydrogel articles for sealing or augmentation of tissue or vessels
US6514534B1 (en) 1998-08-14 2003-02-04 Incept Llc Methods for forming regional tissue adherent barriers and drug delivery systems
US6994686B2 (en) * 1998-08-26 2006-02-07 Neomend, Inc. Systems for applying cross-linked mechanical barriers
US6899889B1 (en) * 1998-11-06 2005-05-31 Neomend, Inc. Biocompatible material composition adaptable to diverse therapeutic indications
US6830756B2 (en) 1998-11-06 2004-12-14 Neomend, Inc. Systems, methods, and compositions for achieving closure of vascular puncture sites
US6458953B1 (en) * 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
CA2359318C (en) 1999-02-01 2009-06-30 Universitat Zurich Biomaterials formed by nucleophilic addition reaction to conjugated unsaturated groups
US6958212B1 (en) 1999-02-01 2005-10-25 Eidgenossische Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
CA2376057A1 (en) * 1999-06-08 2000-12-14 La Jolla Pharmaceutical Company Valency platform molecules comprising aminooxy groups
US7074878B1 (en) * 1999-12-10 2006-07-11 Harris J Milton Hydrolytically degradable polymers and hydrogels made therefrom
US6413507B1 (en) * 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
EP1279406A4 (de) * 2000-04-03 2007-10-24 Santen Pharmaceutical Co Ltd Transporters und arzneimittelabgabesysteme die diese verwenden
US7291673B2 (en) 2000-06-02 2007-11-06 Eidgenossiche Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
CA2414076A1 (en) 2000-06-08 2001-12-13 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
EP1355965B1 (de) 2000-10-19 2012-09-19 Ecole Polytechnique Fédérale de Lausanne (EPFL) Verfahren zur herstellung von blockcopolymeren für multifunktionelle selbstorganisierende systeme
US7829074B2 (en) 2001-10-18 2010-11-09 Nektar Therapeutics Hydroxypatite-targeting poly(ethylene glycol) and related polymers
TWI246524B (en) 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
US7265186B2 (en) * 2001-01-19 2007-09-04 Nektar Therapeutics Al, Corporation Multi-arm block copolymers as drug delivery vehicles
ATE471956T1 (de) 2001-01-30 2010-07-15 Kyowa Hakko Kirin Co Ltd Verzweigte polyalkylenglykole
US6897196B1 (en) * 2001-02-07 2005-05-24 The Regents Of The University Of California pH sensitive lipids based on ortho ester linkers, composition and method
JP4340067B2 (ja) 2001-04-23 2009-10-07 ウィスコンシン アルムニ リサーチ ファウンデイション 二機能性改変ハイドロゲル
US20050276858A1 (en) * 2001-04-23 2005-12-15 Kao Weiyuan J Bifunctional-modified hydrogels
EP1404873B1 (de) 2001-06-21 2013-05-22 Dynavax Technologies Corporation Chimäre immunmodulatorische verbindungen und verfahren zu deren verwendung
GB0116341D0 (en) 2001-07-04 2001-08-29 Smith & Nephew Biodegradable polymer systems
US20040254197A1 (en) * 2001-09-28 2004-12-16 Santen Pharmaceutical Co., Ltd. Injections for eye tissues containing drug bonded to polyethlene glycol
MXPA04004336A (es) * 2001-11-07 2005-05-16 Nektar Therapeutics Al Corp Polimeros ramificados y sus conjugados.
GB0202233D0 (en) 2002-01-31 2002-03-20 Smith & Nephew Bioresorbable polymers
AU2003213152A1 (en) * 2002-02-15 2003-09-09 Nektar Therapeutics Al, Corporation Hydrolytically degradable alkylene oxide based polymers
US20030229333A1 (en) * 2002-02-22 2003-12-11 Control Delivery Systems, Inc. Methods for treating otic disorders
WO2003076490A1 (en) * 2002-03-13 2003-09-18 Beijing Jiankai Technology Co., Ltd. Hydrophilic polymer derivate with y type branch and preparation method of it medical composite comprising above compound
EP1494730B1 (de) * 2002-03-22 2012-01-18 Kuros Biosurgery AG Zusammensetzung für die verstärkung von hartem gewebe
US8282912B2 (en) * 2002-03-22 2012-10-09 Kuros Biosurgery, AG Compositions for tissue augmentation
EP1513853A2 (de) * 2002-05-24 2005-03-16 Neopharm, Inc. Cardiolipin- zusamensetzungen, verfahren zu deren herstellung und verwendung
EA200401565A1 (ru) * 2002-05-24 2005-04-28 Неофарм, Инк. Способ получения кардиолипина или аналога кардиолипина (варианты), способ получения липосомы и композиция кардиолипина для лечения заболеваний (варианты)
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
DK2311432T3 (en) 2002-06-07 2015-02-02 Dyax Corp Modified Kunitz domain polypeptides and their use in reducing ischemia or the onset of a systemic inflammatory response associated with a surgical procedure
GB0216780D0 (en) * 2002-07-19 2002-08-28 Bradford Particle Design Ltd Methods of particle formation
US20050277611A1 (en) * 2002-10-16 2005-12-15 Neopharm, Inc. Cationic cardiolipin analoges and its use thereof
US20060014248A1 (en) * 2003-01-06 2006-01-19 Xencor, Inc. TNF super family members with altered immunogenicity
US7553930B2 (en) * 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
US20050221443A1 (en) * 2003-01-06 2005-10-06 Xencor, Inc. Tumor necrosis factor super family agonists
US20050130892A1 (en) * 2003-03-07 2005-06-16 Xencor, Inc. BAFF variants and methods thereof
US7871607B2 (en) * 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7767429B2 (en) * 2003-03-05 2010-08-03 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20090123367A1 (en) * 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
US7610156B2 (en) * 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
US7642340B2 (en) 2003-03-31 2010-01-05 Xencor, Inc. PEGylated TNF-α variant proteins
EP1610825A2 (de) * 2003-03-31 2006-01-04 Xencor, Inc. Verfahren zur rationellen pegylierung von proteinen
US7332477B2 (en) * 2003-07-10 2008-02-19 Nitto Denko Corporation Photocleavable DNA transfer agent
AU2004268145B2 (en) * 2003-08-29 2010-09-16 Takeda Pharmaceutical Company Limited Poly-PEGylated protease inhibitors
DE602004026747D1 (de) 2003-09-29 2010-06-02 Nitto Denko Corp Biologisch abbaubare polyacetale für die in-vivo-abgabe von polynucleotiden
CA2542353A1 (en) 2003-10-10 2005-04-21 Xencor, Inc. Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
US7786213B2 (en) * 2003-10-15 2010-08-31 The Regents Of The University Of California Biomacromolecule polymer conjugates
US7163677B2 (en) * 2003-10-24 2007-01-16 Nitto Denko Corporation Cationic polymers having degradable crosslinks
US20060182692A1 (en) * 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
GB0329654D0 (en) * 2003-12-23 2004-01-28 Smith & Nephew Tunable segmented polyacetal
JP2008505853A (ja) 2004-04-13 2008-02-28 クインテセンス バイオサイエンシーズ インコーポレーティッド 細胞傷害性薬剤としての非天然のリボヌクレアーゼ複合体
US7642343B2 (en) * 2004-04-16 2010-01-05 Japan Science And Technology Agency PEG-functional nucleic acid conjugate
US8071132B2 (en) * 2004-06-01 2011-12-06 The Penn State Research Foundation Unagglomerated core/shell nanocomposite particles
ATE385423T1 (de) * 2004-06-16 2008-02-15 Straumann Holding Ag Abdeckmembran
US7282584B2 (en) * 2004-06-16 2007-10-16 Straumann Holding Ag Methylene blue
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
TW200624464A (en) * 2004-12-31 2006-07-16 Ind Tech Res Inst Amphiphilic block copolymer and pharmaceutical formulation comprising the same
JP2008530305A (ja) * 2005-02-09 2008-08-07 タイコ ヘルスケア グループ エルピー 合成封止剤
US7674452B2 (en) 2005-03-16 2010-03-09 Nitto Denko Corporation Polymer coating of cells
US20060222596A1 (en) 2005-04-01 2006-10-05 Trivascular, Inc. Non-degradable, low swelling, water soluble radiopaque hydrogel polymer
US7517914B2 (en) 2005-04-04 2009-04-14 Boston Scientificscimed, Inc. Controlled degradation materials for therapeutic agent delivery
US20060228416A1 (en) * 2005-04-06 2006-10-12 Marie-Pierre Faure Methods for modulating topical inflammatory response
JP5329949B2 (ja) 2005-05-31 2013-10-30 エコーレ ポリテクニーク フェデラーレ デ ローザンヌ 遺伝子に基づいた薬物の細胞質送達のためのトリブロックコポリマー
US20070015701A1 (en) * 2005-06-01 2007-01-18 Samuel Zalipsky Macromolecular conjugates of bone morphogenetic protein-7
US8568705B2 (en) 2005-07-18 2013-10-29 Nektar Therapeutics Method for preparing branched functionalized polymers using branched polyol cores
MX2008010841A (es) 2006-02-21 2008-10-27 Nektar Therapeutics Al Corp Polimeros degradables segmentados y conjugados hechos de los mismos.
US8795709B2 (en) 2006-03-29 2014-08-05 Incept Llc Superabsorbent, freeze dried hydrogels for medical applications
AU2007243483B2 (en) 2006-04-24 2012-07-26 Incept, Llc Protein crosslinkers, crosslinking methods and applications thereof
US7872068B2 (en) 2006-05-30 2011-01-18 Incept Llc Materials formable in situ within a medical device
US8840882B2 (en) * 2006-06-23 2014-09-23 Quintessence Biosciences, Inc. Modified ribonucleases
US8298801B2 (en) 2006-07-17 2012-10-30 Quintessence Biosciences, Inc. Methods and compositions for the treatment of cancer
US20090227981A1 (en) * 2007-03-05 2009-09-10 Bennett Steven L Low-Swelling Biocompatible Hydrogels
US20090227689A1 (en) * 2007-03-05 2009-09-10 Bennett Steven L Low-Swelling Biocompatible Hydrogels
EP2136850B1 (de) * 2007-04-13 2012-02-01 Kuros Biosurgery AG Polymergewebeversiegelung
WO2008129245A1 (en) 2007-04-18 2008-10-30 Smith & Nephew Plc Expansion moulding of shape memory polymers
DE602008006181D1 (de) 2007-04-19 2011-05-26 Smith & Nephew Inc Graft-fixierung
ATE547129T1 (de) 2007-04-19 2012-03-15 Smith & Nephew Inc Multimodale formgedächtnis-polymere
US20080287633A1 (en) * 2007-05-18 2008-11-20 Drumheller Paul D Hydrogel Materials
CA2696996C (en) 2007-07-16 2016-03-22 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Antimicrobial constructs
US8067028B2 (en) * 2007-08-13 2011-11-29 Confluent Surgical Inc. Drug delivery device
WO2009026334A2 (en) * 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
JP2010540681A (ja) * 2007-10-08 2010-12-24 クインテッセンス バイオサイエンシズ，インコーポレーテッド リボヌクレアーゼに基づく治療のための組成物及び方法
WO2009102952A2 (en) * 2008-02-13 2009-08-20 Hyperbranch Medical Technology, Inc. Crosslinked polyalkyleneimine hydrogels with tunable degradation rates
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
EP2662090A1 (de) 2008-04-14 2013-11-13 Halozyme, Inc. Modifizierte Hyaluronidasen und ihre Verwendungen bei der Behandlung von Erkrankungen und Zuständen im Zusammenhang mit Hyaluronan
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
WO2010033022A1 (en) * 2008-09-18 2010-03-25 Universiteit Utrecht Holding B.V. Method for the preparation of a controlled release system
CN102227443B (zh) 2008-10-01 2014-05-14 昆特森斯生物科学公司 治疗性核糖核酸酶
WO2010068432A1 (en) 2008-11-25 2010-06-17 Ecole Polytechnique Federale De Lausanne (Epfl) Block copolymers and uses thereof
EA036569B1 (ru) 2008-12-09 2020-11-24 Галозим, Инк. Способ получения полипептида гиалуронидазы ph20
US8637454B2 (en) * 2009-01-06 2014-01-28 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
JP5890182B2 (ja) 2009-02-12 2016-03-22 インセプト エルエルシー ヒドロゲルプラグによる薬物送達
US9463004B2 (en) 2009-05-04 2016-10-11 Incept, Llc. Biomaterials for track and puncture closure
CN102655853B (zh) 2009-09-17 2015-07-29 巴克斯特卫生保健有限公司 透明质酸酶和免疫球蛋白的稳定的复合制剂及其使用方法
WO2011038117A2 (en) 2009-09-23 2011-03-31 The Regents Of The University Of California Chemically amplified response strategies for medical sciences
ES2688093T3 (es) 2010-01-06 2018-10-30 Dyax Corp. Proteínas de unión a calicreína plasmática
WO2011106447A1 (en) * 2010-02-23 2011-09-01 Georgia Tech Research Corporation Biodegradable polymeric networks and methods for manufacturing the same
MX348420B (es) 2010-07-20 2017-06-12 Halozyme Inc Efectos secundarios adversos asociados con la administracion de agentes anti-hialuronano y metodos para mejorar o prevenir los efectos secundarios.
US8524215B2 (en) * 2010-08-02 2013-09-03 Janssen Biotech, Inc. Absorbable PEG-based hydrogels
US8758778B2 (en) 2010-09-16 2014-06-24 The Regents Of The University Of California Polymeric nano-carriers with a linear dual response mechanism and uses thereof
IL269565B2 (en) 2011-01-06 2024-06-01 Dyax Corp Plasma kallikrein binding proteins
US8440309B2 (en) 2011-01-31 2013-05-14 Confluent Surgical, Inc. Crosslinked polymers with the crosslinker as therapeutic for sustained release
ES2634669T3 (es) 2011-02-08 2017-09-28 Halozyme, Inc. Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata
MX341448B (es) 2011-06-17 2016-08-19 Halozyme Inc Metodos de infusion de insulina subcutanea continua con una enzima que degrada a hialuronano.
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
WO2013040501A1 (en) 2011-09-16 2013-03-21 Pharmathene, Inc. Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof
US10226417B2 (en) 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
AU2012328880B2 (en) 2011-10-24 2017-02-23 Halozyme, Inc. Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
US9205150B2 (en) 2011-12-05 2015-12-08 Incept, Llc Medical organogel processes and compositions
WO2013102144A2 (en) 2011-12-30 2013-07-04 Halozyme, Inc. Ph20 polypeptede variants, formulations and uses thereof
NZ700073A (en) 2012-04-04 2016-08-26 Halozyme Inc Combination therapy with an anti - hyaluronan agent and a tumor - targeted taxane
WO2013154753A1 (en) * 2012-04-12 2013-10-17 The Regents Of The University Of California Hydrolytically degradable poly (ethylene glycol) derivatives through introduction of unsaturated methylene ethylene oxide repeat units
WO2014036194A1 (en) 2012-08-28 2014-03-06 The Regents Of The University Of California Polymeric nanocarriers with light-triggered release mechanism
US9278124B2 (en) 2012-10-16 2016-03-08 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
US11116849B2 (en) 2013-04-22 2021-09-14 Ascendis Pharma A/S Hydrogel-linked prodrugs releasing tagged drugs
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
US10711106B2 (en) 2013-07-25 2020-07-14 The University Of Chicago High aspect ratio nanofibril materials
EP3122782A4 (de) 2014-03-27 2017-09-13 Dyax Corp. Zusammensetzungen und verfahren zur behandlung von diabetischem makulaödem
EP3143137A4 (de) 2014-05-14 2017-11-15 Trustees of Dartmouth College Deimmunisiertes lysostaphin und verfahren zur verwendung
EP3186281B1 (de) 2014-08-28 2019-04-10 Halozyme, Inc. Kombinationstherapie mit einer hyaluronanabbauendem enzym und einem immun-checkpoint-hemmer
BR112017007765B1 (pt) 2014-10-14 2023-10-03 Halozyme, Inc Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
BR112018011622A2 (pt) 2015-12-11 2018-11-27 Dyax Corp método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae
CN108525016B (zh) * 2017-03-01 2020-09-22 中国科学院化学研究所 基于可快速降解化学键的peg水凝胶及其制备方法与应用
CN108659227B (zh) * 2017-03-30 2020-11-06 北京键凯科技股份有限公司 一种y型分支的亲水性聚合物羧酸衍生物的制备方法
WO2018177055A1 (zh) * 2017-03-30 2018-10-04 北京键凯科技股份有限公司 一种y型分支的亲水性聚合物羧酸衍生物的制备方法
AU2018290281B2 (en) 2017-06-22 2021-12-16 Vertex Pharmaceuticals Incorporated Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use
CA3075027A1 (en) * 2017-09-05 2019-03-14 Torque Therapeutics, Inc. Reversible linkers and use thereof
US11173212B2 (en) * 2017-09-28 2021-11-16 Indian Institute Of Science Education And Research Supramolecular protein assemblies with advanced functions and synthesis thereof
US10980913B2 (en) 2018-03-05 2021-04-20 Ethicon Llc Sealant foam compositions for lung applications
US20190351031A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
WO2020140101A1 (en) 2018-12-28 2020-07-02 Catalyst Biosciences, Inc. Modified urokinase-type plasminogen activator polypeptides and methods of use
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use
CA3167336A1 (en) 2020-01-13 2021-07-22 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
US20250129132A1 (en) * 2021-09-21 2025-04-24 University Of Washington Genetically encoded and exogenously triggered protein-protein ligation
WO2025227129A2 (en) 2024-04-25 2025-10-30 Starrock Pharma Llc Delivery vehicles comprising proglucagon derived polypeptides and anabolic polypeptides and uses thereof
US20250341516A1 (en) 2024-05-01 2025-11-06 BioLegend, Inc. Compositions for use with multiple fluorophores and methods of using

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3149006A (en) 1963-01-31 1964-09-15 William T Abel Prevention of embrittlement of metals
US3419006A (en) 1966-08-08 1968-12-31 Union Carbide Corp Novel dressing and use thereof
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3963805A (en) 1974-10-30 1976-06-15 Union Carbide Corporation Water swellable poly(alkylene oxide)
AU537741B2 (en) 1979-03-21 1984-07-12 British Technology Group Limited Controlled release compositions
JPS585320A (ja) 1981-07-01 1983-01-12 Toray Ind Inc グラフト共重合体
CA1191006A (en) 1982-01-14 1985-07-30 Sekisui Kaseihin Kogyo Kabushiki Kaisha Sheet for forming sleeve and process for producing the same
JPH0610922B2 (ja) † 1983-12-09 1994-02-09 ブリティッシュ・テクノロジー・グループ・リミテッド ポリマ−状物質
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
WO1992000748A1 (en) 1990-07-06 1992-01-23 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5410016A (en) * 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5192743A (en) * 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
NZ249770A (en) † 1992-02-28 1996-09-25 Univ Texas Biodegradable, polymerisable, substantially water soluble macromer comprising at least one water soluble region, at least one degradable region and at least two free radical polymerisable regions separated by at least one degradable region
AU4406793A (en) 1992-06-04 1993-12-30 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
US5514379A (en) 1992-08-07 1996-05-07 The General Hospital Corporation Hydrogel compositions and methods of use
AU4899093A (en) 1992-10-13 1994-04-28 Pacesetter Ab Compound and method of applying anti-fouling coatings on medical devices
US5321095A (en) * 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
US5618528A (en) * 1994-02-28 1997-04-08 Sterling Winthrop Inc. Biologically compatible linear block copolymers of polyalkylene oxide and peptide units
US5730968A (en) * 1994-03-31 1998-03-24 Sterling Winthrop Inc. Segmented chelating polymers as imaging and therapeutic agents
JPH10501814A (ja) 1994-06-17 1998-02-17 ユニバーシティ・オブ・ネブラスカ・ボード・オブ・リージェンツ 生物的作用物質用のイン・シツゲル形成デリバリービヒクルおよびその使用方法
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5648088A (en) 1995-03-06 1997-07-15 Ethicon, Inc. Blends of absorbable polyoxaesters containing amines and/or amide groups
US5597579A (en) 1995-03-06 1997-01-28 Ethicon, Inc. Blends of absorbable polyoxaamides
US5607687A (en) * 1995-03-06 1997-03-04 Ethicon, Inc. Polymer blends containing absorbable polyoxaesters
US5962023A (en) * 1995-03-06 1999-10-05 Ethicon, Inc. Hydrogels containing absorbable polyoxaamides
PT876165E (pt) 1995-12-18 2006-10-31 Angiotech Biomaterials Corp Composicoes de polimeros reticulados e processos para a sua utilizacao
US5610241A (en) * 1996-05-07 1997-03-11 Cornell Research Foundation, Inc. Reactive graft polymer with biodegradable polymer backbone and method for preparing reactive biodegradable polymers
US20020064546A1 (en) * 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
US6214966B1 (en) * 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US6258351B1 (en) * 1996-11-06 2001-07-10 Shearwater Corporation Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
WO1999034833A1 (en) * 1998-01-07 1999-07-15 Shearwater Polymers, Incorporated Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom
US6284832B1 (en) † 1998-10-23 2001-09-04 Pirelli Cables And Systems, Llc Crosslinked conducting polymer composite materials and method of making same
US6348558B1 (en) * 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom

Also Published As

Publication number Publication date
DE69823055T3 (de) 2007-09-20
US6432397B1 (en) 2002-08-13
US7018624B2 (en) 2006-03-28
DK1028753T4 (da) 2007-06-25
DE69823055T2 (de) 2005-03-03
AU752747B2 (en) 2002-09-26
US20020032281A1 (en) 2002-03-14
ES2219869T5 (es) 2007-11-01
WO1999022770A1 (en) 1999-05-14
PT1028753E (pt) 2004-08-31
EP1028753A1 (de) 2000-08-23
DE69823055D1 (de) 2004-05-13
CA2304976A1 (en) 1999-05-14
AU6029198A (en) 1999-05-24
JP2001523637A (ja) 2001-11-27
US6558658B2 (en) 2003-05-06
ES2219869T3 (es) 2004-12-01
CA2304976C (en) 2005-09-20
EP1028753B1 (de) 2004-04-07
DK1028753T3 (da) 2004-08-09
JP3884615B2 (ja) 2007-02-21
EP1028753B2 (de) 2007-03-07
US20030202955A1 (en) 2003-10-30
US6258351B1 (en) 2001-07-10

Similar Documents

Publication Publication Date Title
DE69823055D1 (de) Abgabe von polyethylene glycol-molekül- konjugaten aus abbaubarem hydrogel
DK0973819T3 (da) Ikke-antigene forgrenede polymerkonjugater
ATE368054T1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
CA2174325A1 (en) Non-antigenic branched polymer conjugates
DE69913316D1 (de) Abbaubare, heterobifunktionelle polyethylenglykolacrylate, sowie damit herstellbare gele und konjugate
ATE332918T1 (de) Neoglycoproteine
TR199700845T1 (xx) Aerojel'lerin tar�mda kullan�lmas�.
NO20015584L (no) Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling
DK1061900T4 (da) Dermale præparater
ATE244556T1 (de) Biologisch abbaubare ph/thermosensitive hydrogele zur verzörgerten freisetzung biologisch aktiver stoffe
DE60331049D1 (de) Konjugate von zytotoxischen mitteln und biologisch aktiven peptiden
DE69942231D1 (de) Ortspezifische duale pegylation von proteine
BR0014652A (pt) Fabricação de conjugados de agente terapêutico-poliglutamato
DE59809588D1 (de) Arzneistoffträgerpartikel für die gewebespezifische arzneistoffapplikation
MY131553A (en) Lyophilized formulation of polyethylene oxide modified proteins with increased self-life
TR200101751T2 (tr) Poliol-IFN-beta konjugatları
ATE356638T1 (de) Hydrolytisch abbaubare carbamatderivate von polyethylenglykol
DK0839026T3 (da) Micellære polyether-blokcopolymerkompositioner til målretning af biologiske midler
ATE395906T1 (de) Träger in partikelform zur verbesserung der oral- absorption von wikstoffen
GR3030732T3 (en) Pharmaceutical compositions including a drug, a cross-linked polymeric substance, an oil, and a surface active agent.
ES2168457T3 (es) Composiciones farmaceuticas que comprenden una superoxido dismutasa.
ATE281155T1 (de) Medikamentöse verabreichung von proteinen aus polymergemischen
ATE380202T1 (de) Interaktionssystem zur präsentation und entfernung von substanzen
BR9712904A (pt) Agentes de tratamento de plantas
DE69625918D1 (de) Lang wirksames mittel zur rektalen verabreichung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1028753

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 1028753

Country of ref document: EP